Schrödinger to Participate in Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in the following conferences in March: TD Cowen 46th Annual Health Care Conference: Fireside chat on Tuesday, March 3, 2026 at 9:50 a.m. E.T. Leerink Global Healthcare Conference 2026: Fireside chat on Tuesday, March 10, 2026 at 1:40 p.m. E.T. KBCM Healthcare Forum: Fireside chat on Tuesday, March 17, 2026 at 9:00 a.m. E.T. The live discussions can be accessed in the “Investors” section.

Business Wire • 15 hours ago

Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga • Feb 19, 2026

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on February 13, 2026, the company granted (i) non-statutory stock options to purchase 9,600 shares of the company's common stock to two newly hired employees and (ii) restricted stock units (RSUs) with respect to 18,250 shares of the company's common stock to eight newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committe.

Business Wire • Feb 18, 2026

Schrödinger to Announce Fourth Quarter and Full-Year 2025 Financial Results on February 25

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) will report its fourth quarter and full-year 2025 financial results on Wednesday, February 25, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its comput.

Business Wire • Feb 11, 2026

Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its physics+AI computational platform and serving as a global leader in computational molecular discovery. “In 2025, we witnessed the continued impact of scaling ‘physics+AI' to solve the challenges of data scarcity and to accelerate the discovery of differentiated molecules. We.

Business Wire • Jan 12, 2026

Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger's widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows. “As a lead.

Business Wire • Jan 9, 2026

Schrodinger to offer Eli Lilly's AI drug discovery platform on its software

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.

Reuters • Jan 9, 2026

Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade

The consensus price target hints at a 46.2% upside potential for Schrodinger (SDGR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Dec 12, 2025

Unlocking Hidden Value In Schrodinger's Box

Schrodinger's shares have declined sharply in recent weeks, due largely to soft guidance for the fourth quarter. There is little reason to believe that this is anything more than a temporary headwind caused by market conditions though. In addition, recent cost reductions and the end of internal drug development should significantly reduce cash burn in 2026.

Seeking Alpha • Dec 2, 2025

Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now

Schrodinger (SDGR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Investment Research • Nov 10, 2025